search for




 

The Effect of Epiretinal Membrane on Dexamethasone Implant for Branch Retinal Vein Occlusion Macular Edema
망막분지정맥폐쇄에 의한 황반부종에서 망막전막이 덱사메타손 삽입물 치료 효과에 미치는 영향
JKOS 2019 Sep;60(9):843-50
Published online September 15, 2019;  https://doi.org/10.3341/jkos.2019.60.9.843
Copyright © 2019 The Korean Ophthalmological Society.
PDF Download Count: 85 / View Count: 92

Mirinae Jang, MD1, Jin Young Kim, MD1, Sang-Yoon Lee, MD1, Jin Ho Jeong, MD, PhD1, Eun Kyoung Lee, MD1,2
장미리내1 · 김진영1 · 이상윤1 · 정진호1 · 이은경1,2

Department of Ophthalmology, Jeju National University School of Medicine1, Jeju, Korea
Department of Ophthalmology, Seoul National University College of Medicine2, Seoul, Korea
제주대학교 의학전문대학원 안과학교실1, 서울대학교 의과대학 안과학교실2
Received February 12, 2019; Revised April 11, 2019; Accepted August 16, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Purpose: To evaluate the effect of epiretinal membrane (ERM) on the outcomes of intravitreal dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) treatment for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
Methods: Thirty eyes of 30 patients who received Ozurdex treatment for ME secondary to BRVO, and were followed-up for at least 6 months were retrospectively reviewed. Patients were divided into two groups based on the presence (ERM [+] or absence ERM [-]) of ERM at baseline. The best-corrected visual acuity (BCVA), central foveal thickness (CFT), recurrence of ME, and retreatment rate were evaluated at baseline, 1, 3, and 6 months after Ozurdex injection.
Results: Ten eyes of 30 eyes (33%) showed ERM at baseline. While the mean CFT was significantly reduced at 1 month after Ozurdex injection, it began to increase gradually thereafter in both groups. The ERM (+) group showed a significantly higher mean CFT than the corresponding values of the ERM (-) group at 1 (p = 0.022) and 6 months (p = 0.001) after Ozurdex injection. However, no significant difference was found in the BCVA between the two groups at every visit. The proportion of eyes with ME was significantly higher in the ERM (+) group (90%) than that in the ERM (-) group (35%) at 6 months after Ozurdex injection (p = 0.009). There were no significant differences between the two groups in the percentage of retreatment, time to retreatment, and type of materials used for retreatment.
Conclusions: In patients with ME secondary to BRVO, the treatment effect of Ozurdex was low and the duration of treatment was short when ERM was concurrently present. However, the presence of ERM did not significantly affect visual outcomes after treatment with Ozurdex.
Keywords : Branch retinal vein occlusion, Epiretinal membrane, Intravitreal dexamethasone implant, Macular edema

 

October 2019, 60 (10)